Inhibition of oxidative phosphorylation (OXPHOS) is a promising therapeutic strategy in Acute 39 Myeloid Leukemia (AML), but patients respond heterogeneously. Through chemically 40 interrogation of 200 sequenced specimens, we identified Mubritinib as a strong in vitro and in 41 vivo anti-leukemic compound, acting through ubiquinone-dependent inhibition of Electron 42 Transport Chain complex I (ETC1). ETC1 targeting showed selective toxicity against a subgroup 43 of chemotherapy-resistant leukemias exhibiting OXPHOS hyperactivity, high expression of 44 mitochondrial activity-related genes, and mutations affecting NPM1, FLT3 and DNMT3A.
6 cellular acidification rates (ECAR) in Mubritinib treated cells, a phenomenon which could be 194 rescued by 2-deoxy-D-glucose (2-DG, an inhibitor of glycolysis, Fig. S3d-e ), suggesting an 195 upregulation of glycolytic activity upon treatment. Accordingly, Mubritinib treated cells showed 196 increased intracellular and extracellular lactate concentrations ( Fig. S3f-g) . Taken together, 197 these data indicate that Mubritinib treatment of AML cells induces a switch from OXPHOS 198 towards glycolytic metabolism.
199
In addition, 2',7' -dichlorofluorescin diacetate (DCFDA) staining of Mubritinib-sensitive human 200 (OCI-AML3) or murine (MLL-AF9, Fig. S3h ) AML cells revealed reactive oxygen species (ROS) 201 accumulation upon Mubritinib treatment (Fig. 3o ). LC/MS analyses highlighted decreased levels 202 of reduced glutathione (Fig. 3p ) concomitant with increased levels of oxidized glutathione ( Fig.   203 3q) in presence of Mubritinib, confirming the induction of oxidative stress in treated cells. In 204 response to treatment, sensitive AML cells underwent apoptotic death as assessed by flow 205 cytometry using Annexin V and propidium iodide staining in OCI-AML3 cells ( Fig. 3r ) and MLL-206 AF9 cells (Fig. S3i ). Last but not least, we monitored the OXPHOS activity profiles of genetically 207 diverse primary AML specimens (see list in Table S6 ) that are either sensitive (n=11, GI50 < 208 100nM) or resistant (n=12, GI50> 5μM) to Mubritinib treatment. We found that basal 209 mitochondrial oxygen consumption and proton leak rates are significantly higher in sensitive 210 leukemias as compared to resistant AMLs, while extracellular acidification rates do not differ 211 between the two groups of specimens . The results are in line with our 212 observation that expression levels of genes involved in mitochondrial activity correlate with 213 Mubritinib sensitivity Fig. 2g ) and suggest that Mubritinib-sensitive AMLs are more heavily 214 relying on OXPHOS for energy production than Mubritinib-resistant leukemias (Fig. 2g) . In 215 addition, as proton leak mediates a decrease in OXPHOS-induced ROS 42 , these results also 216 highlight a possible mechanism through which Mubritinib-sensitive AMLs are able to withstand 217 such sustained basal OXPHOS hyperactivity.
219

Mubritinib is a novel ETC complex I inhibitor 220
In order to further dissect Mubritinib's mode of action, we next monitored changes in protein and 221 phospho-protein abundance upon Mubritinib treatment using Stable Isotope Labeling by Amino 222 acids in cell Culture (SILAC)-proteomic ( Fig. 4a ) and phospho-proteomic ( Fig. 4b) approaches, 223 respectively. In these experiments, pyruvate dehydrogenase (PDH) E3 subunit was the most 224 prominent down-regulated protein in Mubritinib treated cells ( Fig. 4a ), while the inactivating 225 phosphorylation 43 of serine 293 of PDH E1 subunit was markedly increased upon treatment 226 (Fig. 4b ). Although we could confirm the inhibitory effect of Mubritinib on PDH using a cell-based 227 enzymatic activity assay (Fig. 4c, p=0 .0098), we found that this effect was in fact indirect as 228 Mubritinib (25μM, cell-free context) did not inhibit the activity of the immuno-captured complex 229 ( Fig. 4d ).
230
In order to identify Mubritinib's target pathway, we then carried out a whole-genome 231 CRISPR/Cas9 screen in the presence or absence of Mubritinib treatment ( Fig. S4a and Read 232 files 1-3), as previously described 44 . For this purpose, we used the B cell precursor leukemia 233 cell line NALM-6, which, similar to poor outcome AML patient cells, is sensitive to Mubritinib 234 ( Fig. S4a) , but resistant to the ERBB2 inhibitor Lapatinib (GI50>10μM, not shown). This chemo-235 genomic screen notably identified a synthetic lethal interaction between Mubritinib treatment 236 and loss of Glutamic-Oxaloacetic Transaminase 1 (GOT1) expression, a pyridoxal phosphate-237 dependent enzyme with aspartate aminotransferase activity (Fig. 4e ). Accordingly, shRNA hit 238 validations ( Fig. S4b-c) revealed, among others, that silencing of GOT1 expression in OCI-
239
AML3 cells leads to a sensitization to Mubritinib treatment (Fig. S4b) . Interestingly, recent 240 studies reported a similar synthetic lethal interaction between GOT1 knock-out and inhibitors of 241 the electron transport chain (ETC). These studies showed that a major role of respiration in 242 proliferating cells is to provide electron acceptors for aspartate synthesis, an alpha-amino acid 243 7 that, in the context of ETC inhibition, can only be replenished through GOT1 activity 45,46 . 244 Indeed, and similar to ETC inhibitors, Mubritinib treatment in OCI-AML3 cells led to a four-fold 245 decrease in aspartate concentrations (Fig. 4f ).
246
So as to investigate whether Mubritinib indeed behaves as an ETC inhibitor in AML cells, we 247 compared the inhibition pattern induced by Mubritinib treatment with that of known ETC 248 inhibitors (Deguelin (complex I), 47, 48 and Oligomycin (complex V)) for 56 primary AML samples 249 (see patient characteristics in Supplementary Table S7 ). We found that the two ETC inhibitors' 250 inhibitory patterns are highly similar to that of Mubritinib (r=0.9, p<0.0001 for Deguelin, Fig. 4g 251 and r=0.7, p<0.001 for Oligomycin, Fig. S4d ). These results strongly suggest that, in the context 252 of AML, Mubritinib targets the same molecular pathway as ETC inhibitors.
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To test whether Mubritinib directly inhibits the ETC, we next carried out cell-free enzymatic 254 activity assays for each complex of the chain. We found that, while Mubritinib did not impair the 
259
suggesting that Mubritinib may bind at or near the ubiquinone binding site, similar to what is 260 described for Rotenone 50-52 . Indeed, ubiquinone supplementation was able to rescue the 261 inhibition of NADH oxidation induced by Mubritinib treatment, demonstrating that Mubritinib acts 262 as a ubiquinone-dependent inhibitor of NADH dehydrogenase (Fig. 4i ). In addition, in agreement 263 with an inhibitory effect on ETC complex I, Mubritinib-treated OCI-AML3 cells exhibited 264 decreased NAD/NADH concentration ratios ( Fig. S4l ). NADH being the product, and NAD, the 265 substrate of PDH, these results might explain the indirect effect of Mubritinib on PDH activity.
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In order to test whether the anti-leukemic activity of Mubritinib is indeed mediated by the 267 inhibition of ETC complex I activity, we compared the anti-leukemic potential of 15 different 268 Mubritinib analogs in cellular assays (GI50) to their cell-free activity on ETC complex I (IC50).
269
We found that GI50 and IC50 values strongly correlate in both human (OCI-AML3) and murine 270 (MLL-AF9) AML cells (r=0.9, p<0.0001 for both models, Fig. 4j and Table S8 ). Instead of ETC 271 complex I, Saccharomyces cerevisiae expresses a nucleus-encoded rotenone-insensitive 272 NADH dehydrogenase called NDI1 53 , known to be able to restore OXPHOS activity in complex 273 I deficient human cells 54 . Accordingly, ectopic expression of NDI1 in two different human AML 274 cell lines led to a rescue of cell viability in both Rotenone-and Mubritinib-treated cells, thus 275 demonstrating that Mubritinib's antileukemic activity is mainly mediated by its ability to inhibit 276 ETC complex I activity .
277
Based on preliminary structure activity relationship studies, we propose a model of interaction 278 between Mubritinib and the ubiquinone binding pocket of NADH dehydrogenase ( Fig. 4m ).
279
Overall, our findings on Mubritinib's mechanism of action in AML are summarized in Fig. 5a .
280
Mubritinib significantly delays AML development in vivo 281
We next assessed the anti-leukemic potential of Mubritinib in vivo using the syngeneic MLL-AF9 282 murine AML model ( Fig. 5b ). MLL-AF9 cells express high levels of HOX-network genes and are 283 highly sensitive to Mubritinib treatment in vitro ( Fig. S3i ) and thus represent a relevant AML 284 model to study Mubritinib's activity. Furthermore, the cells chosen for this study were easily 285 trackable due to engineered expression of the fluorescent marker tdTomato. Within the treated 286 cohort, one mouse died at day 20, probably due to compulsive gavage, as we did not detect 287 overt leukemia development in its bone marrow ( Fig. S5a ). Upon analysis at day 29, mouse 288 weights before and after treatment were not altered, both in Mubritinib and vehicle treated 289 groups ( Fig. 5c ), suggesting that the treatment was overall well tolerated.
290
By histology, we found that the bone marrow and the spleens of treated animals contained less 291 leukemic blasts than control animals ( Fig. 5d ). Accordingly, the frequencies of tdTomato positive 
298
5h). Importantly, and in agreement with our observation that Mubritinib treatment does not affect 299 the proliferation of normal hematopoietic CD34 + cells in vitro (Fig. 1d ), the absolute number of 300 tdTomato negative nucleated bone marrow cells was conserved after Mubritinib treatment (Fig. 
301
S5d).
302
In order to investigate the consequences of Mubritinib treatment on normal hematopoiesis, we 303 treated non-transplanted PeP3B mice according to the experimental scheme in Fig. S5e . Upon 304 analysis of the bone marrow of treated animals at day 29, we found no significant change in the 305 absolute number of hematopoietic cells within stem or differentiated compartments ( Fig. S5f-n ).
306
Analysis of blood samples at day 29 showed no significant change in neutrophil or platelet 307 counts but revealed consistent decreases in red blood cell numbers as well as hemoglobin, 308 hematocrit and haptoglobin measurements, all within the normal range ( Fig. S5o-t Hexokinase-1 (HK1), encoding an enzyme that catalyzes the first step of glucose metabolism.
332
This result is in line with our observation that Mubritinib-treated cells switch from oxidative 333 phosphorylation to glycolysis and is consistent with our finding that Mubritinib inhibits the ETC.
334
This study confirms, in the context of primary AML specimens, the recent observations from 335 others indicating that inhibition of mitochondrial function is a promising therapeutic strategy in 336 AML 21, 22, 24, [26] [27] [28] . Importantly, it also identifies and characterizes for the first time AML genetic 337 subtypes most susceptible to respond to mitochondrial targeting. We show that, similar to 338 normal CD34-positive cells, chemotherapy-sensitive, favorable cytogenetic risk primary AMLs 339 do not require oxidative phosphorylation for energy production and exhibit strong transcriptomic 340 hallmarks of hypoxia, which is consistent with recent observations made in AML xenografts 25 .
341
Also in line with these findings, resistance to Mubritinib associated with mutations affecting the 342 RAS/MAPK signaling pathway, which are known inducers of glycolytic metabolism 55,56 . In stark 343 contrast, Mubritinib sensitivity associated with poor outcome AMLs enriched within the normal 344 karyotype subtype, overexpressing HOX network genes, and carrying mutations affecting 345 NPM1, FLT3-ITD as well as genes involved in the regulation of DNA methylation (DNMT3A, 346 TET2, IDH1, and IDH2). Sensitivity in primary AML specimens also strongly correlated with 347 increased expression of gene modules associated with mitochondrial activity, including 348 mitochondrial respiration and indeed, direct metabolic profiling identified an association between 349 Mubritinib sensitivity and OXPHOS hyperactivity in primary AML specimens.
351
In summary, using an unbiased chemo-genomic approach, our work identifies Mubritinib as a 352 direct and ubiquinone-dependent NADH dehydrogenase inhibitor with strong in vitro and in vivo 353 anti-leukemic activity. Importantly, we identify a genetically distinct OXPHOS-dependent 354 population of poor outcome leukemias most susceptible to respond to ETC1-targeting, thus 
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Materials and correspondance 413 Further information and requests for resources and reagents should be directed to and will be 414 fulfilled by the Lead Contact, Guy Sauvageau (guy.sauvageau@umontreal.ca). Table S1 ). c, Set-up and d, result of 419 the validation screen (see also Table S3 ). Mubritinib GI50 values 431 according to b, cytogenetic risk classes, c, genetic subgroups and d, the presence of co-432 occurring FLT3-ITD, DNMT3A and NPM1-mutations (see also Figure S2b ). e, Most differentially 433 expressed genes between Mubritinib-resistant and -sensitive specimens, highlighting HOX-434 network genes in bold (see also Table S6 ). Statistical assessments were performed using the unpaired two-tailed t-test. In 
415
Figure legends
475
PSST and ND1 are shown as blue, purple and green ribbons, respectively. Selected sidechains 476 lining the site are depicted as sticks and Fe-S cluster N2 is shown as spheres. In a-b, statistical 477 assessments were performed using the unpaired two-tailed t-test and the FDR q-value cut-off of 478 5% is indicated by the dotted line. In c-d and f, statistical assessments were performed using 479 the Mann-Whitney test. In e, statistical assessments were performed using the Wilcoxon rank-480 sum test and the false discovery rate (FDR) method. In i, statistical assessments were 481 performed using the two-sided unpaired t-test. In j, statistical assessments were performed 482 using the Pearson correlation test. In k and l, statistical assessments were performed using 
Flow cytometry analyses
751
Antibodies used in the study are listed in the Key Resources 
775
The R package WGCNA 38 was used to perform a weighted correlation network analysis with 
810
A volume of 300μl of ice-cold water and 600μl of ice-cold methylene chloride were added to the 811 lysates. Samples were vortexed and allowed to rest on ice for 10 min for phase separation 812 followed by centrifugation at 4,000rpm for 5min. The upper aqueous layer was transferred to a 813 fresh pre-chilled tube. Samples were dried by vacuum centrifugation operating at -4°C
814
(Labconco) and stored at -80°C until ready for LC-MS/MS data collection.
815
For targeted semi-quantitative analysis of Amino acids or nucleotides LC-MS/MS was utilized.
816
Specimens were first re-suspended in 50μL of water and clarified by centrifugation for 5 min at 
823
These data are considered semi-quantitative due to potential uncorrected matrix effects.
824
For nucleotide analysis, a volume of 5μL was injected an Agilent 6430 
830
The flow rate was set for 0.4mL/min. The column was then re-equilibrated at 100% solvent A 831 for 6 min before the next injection.
832
After extensive re-equilibration to a different solvent system, the same column and instrument 833 were used for amino acid and citric acid cycle intermediate detection. Separation was achieved 834 using a gradient starting gradient started at 100% mobile phase A (0.2% formic acid in water) 835 with a 2min hold followed with a 6min gradient to 80% B (0.2 % formic acid in MeOH) at a flow 836 rate of 0.4 ml/min and column temperature of 10°C. This was followed by a 5min hold time at 837 100% mobile phase B and a subsequent re-equilibration time (6 min) before the next injection.
838
LC/MS proteomics and phospho-proteomics approaches.
839
Protein extraction and enzymatic digestion. 
850
Phosphopeptide isolation and fractionation.
851
Tryptic digests were subjected to enrichment on TiO 2 beads as described previously 63 . Sample 
882
protein, and site identification was set to 1% and was calculated using decoy database 883 approach. The minimum peptide length was set to 6, and the 'peptide requantification' function 884 was enabled. The option match between runs (1 min time tolerance) was enabled to correlate 885 identification and quantitation results across different runs. In addition to an FDR of 1% set for 886 peptide, protein and phosphosite identification levels, we considered only phosphosites for 887 which localization confidence was higher than 75%. Relative quantification of the peptides 888 against their heavy-labeled counterparts was performed with MaxQuant using area under 3D 889 pepride peak shapes 66,67 .
890
Whole genome CRISPR/Cas9 screen.
891
The Extended Knockout (EKO) pooled lentiviral library of 278,754 sgRNAs targeting 19,084
892
RefSeq genes, 3,872 hypothetical ORFs and 20,852 alternatively spliced isoforms was 893 introduced within a clone of the NALM-6 pre-B lymphocytic cells line with a doxycycline-894 inducible Cas9 was described previously 44 . NALM-6 cells at 200,000 cells per ml were exposed 
